Sunitinib in metastatic renal cell carcinoma patients with brain metastases (pages 501–509)
Martin E. Gore, Subramanian Hariharan, Camillo Porta, Sergio Bracarda, Robert Hawkins, Georg A. Bjarnason, Stéphane Oudard, Se-Hoon Lee, Giacomo Carteni, Alejandra Nieto, Jinyu Yuan and Cezary Szczylik
Version of Record online: 22 SEP 2010 | DOI: 10.1002/cncr.25452
Three hundred twenty-one patients with brain metastases from RCC were enrolled in a global, open-label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.